AR096620A1 - Derivado de aminotriazina y composición farmacéutica que lo comprende - Google Patents
Derivado de aminotriazina y composición farmacéutica que lo comprendeInfo
- Publication number
- AR096620A1 AR096620A1 ARP140102276A ARP140102276A AR096620A1 AR 096620 A1 AR096620 A1 AR 096620A1 AR P140102276 A ARP140102276 A AR P140102276A AR P140102276 A ARP140102276 A AR P140102276A AR 096620 A1 AR096620 A1 AR 096620A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkyloxy
- independently
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos con una actividad antagonista del receptor P2X3 y/o P2X2/3. Reivindicación 1: Un compuesto, caracterizado porque tiene la fórmula (1), en donde Rᵃ y Rᵇ son ambos átomos de hidrógeno o Rᵃ y Rᵇ se toman juntos para formar oxo, tioxo o =N-Rˣ; Rᵈ y Rᵉ son ambos átomos de hidrógeno o Rᵈ y Rᵉ se toman juntos para formar oxo, tioxo o =N-Rʸ; Rˣ y Rʸ son cada uno, de modo independiente, un átomo de hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, un grupo heterocíclico no aromático sustituido o no sustituido, arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido; R⁴ᵃ es cada uno, de modo independiente, un átomo de hidrógeno o alquilo sustituido o no sustituido; R⁴ᵇ es cada uno, de modo independiente, un átomo de hidrógeno o alquilo sustituido o no sustituido; o R⁴ᵃ y R⁴ᵇ unidos al mismo átomo de carbono se toman juntos para formar oxo o tioxo; n es un número entero de 1 a 4; R² es cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, un grupo heterocíclico no aromático sustituido o no sustituido, arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido; R⁹ es cada uno, de modo independiente, halógeno, hidroxi, carboxi, ciano, nitro, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, alquiloxi sustituido o no sustituido, alqueniloxi sustituido o no sustituido, alquiniloxi sustituido o no sustituido, alquiltio sustituido o no sustituido, alqueniltio, sustituido o no sustituido, alquiniltio sustituido o no sustituido, acilo sustituido o no sustituido, alquiloxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo sustituido o no sustituido, carbamoilo sustituido o no sustituido, amino sustituido o no sustituido, sulfamoilo sustituido o no sustituido, sulfonilo sustituido, sulfinilo sustituido, cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, un grupo heterocíclico no aromático sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, cicloalquiloxi sustituido o no sustituido, cicloalqueniloxi sustituido o no sustituido, heterocicliloxi no aromático sustituido o no sustituido, ariloxi sustituido o no sustituido o heteroariloxi sustituido o no sustituido; R⁹ es cada uno, de modo independiente, halógeno, hidroxi, carboxi, ciano, nitro, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, alquiloxi sustituido o no sustituido, alqueniloxi sustituido o no sustituido, alquiniloxi sustituido o no sustituido, alquiltio sustituido o no sustituido, alqueniltio sustituido o no sustituido, alquiniltio sustituido o no sustituido, acilo sustituido o no sustituido, alquiloxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo sustituido o no sustituido, carbamoilo sustituido o no sustituido, amino sustituido o no sustituido, sulfamoilo sustituido o no sustituido, sulfonil o sustituido, sulfinilo sustituido, cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, un grupo heterocíclico no aromático sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, cicloalquiloxi sustituido o no sustituido, cicloalqueniloxi sustituido o no sustituido, heterocicliloxi no aromático sustituido o no sustituido, ariloxi sustituido o no sustituido o heteroariloxi sustituido o no sustituido; s y s son cada uno, de modo independiente, un número entero de 0 a 3; R²⁰ᵃ es cada uno, de modo independiente, un átomo de hidrógeno, hidroxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido o alquiloxi sustituido o no sustituido; R²⁰ᵇ es cada uno, de modo independiente, un átomo de hidrógeno, hidroxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido o alquiloxi sustituido o no sustituido; o R²⁰ᵃ y R²⁰ᵇ unidos al mismo átomo de carbono o los átomos de carbono diferentes se toman juntos para formar cicloalcano sustituido o no sustituido, cicloalqueno sustituido o no sustituido o un anillo heterocíclico no aromático sustituido o no sustituido; siempre que todos los R²⁰ᵃ y R²⁰ᵇ no sean átomos de hidrógeno al mismo tiempo; u es un número entero de 1 a 4; y R¹³ es un átomo de hidrógeno o alquilo sustituido o no sustituido; siempre que se excluyan los compuestos de fórmula (2) ó (3); o su sal farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013125134 | 2013-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096620A1 true AR096620A1 (es) | 2016-01-20 |
Family
ID=52022364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102276A AR096620A1 (es) | 2013-06-14 | 2014-06-13 | Derivado de aminotriazina y composición farmacéutica que lo comprende |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9732060B2 (es) |
| EP (1) | EP3009432B1 (es) |
| JP (1) | JP6132371B2 (es) |
| KR (2) | KR101813411B1 (es) |
| CN (1) | CN105452234B (es) |
| AR (1) | AR096620A1 (es) |
| AU (1) | AU2014279116B2 (es) |
| BR (1) | BR112015031079B1 (es) |
| CA (1) | CA2915325C (es) |
| DK (1) | DK3009432T3 (es) |
| EA (1) | EA030198B1 (es) |
| ES (1) | ES2675528T3 (es) |
| IL (1) | IL243042A0 (es) |
| MX (1) | MX362995B (es) |
| PH (1) | PH12015502775A1 (es) |
| PL (1) | PL3009432T3 (es) |
| SG (1) | SG11201510179PA (es) |
| TR (1) | TR201809085T4 (es) |
| TW (1) | TWI637949B (es) |
| WO (1) | WO2014200078A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102395571B (zh) | 2009-02-13 | 2015-12-16 | 盐野义制药株式会社 | 三嗪衍生物及含有该三嗪衍生物的药物组合物 |
| WO2012020742A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
| RU2565073C2 (ru) | 2010-08-10 | 2015-10-20 | Сионоги Энд Ко., Лтд. | Триазиновое производное и включающая его фармацевтическая композиция, обладающая анальгетической активностью |
| TWI637949B (zh) * | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| US9988373B2 (en) | 2013-12-26 | 2018-06-05 | Shionogi & Co., Ltd. | Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same |
| JPWO2016084922A1 (ja) * | 2014-11-28 | 2017-09-07 | 塩野義製薬株式会社 | １，２，４−トリアジン誘導体およびその医薬組成物 |
| EP3957627B1 (en) | 2015-04-24 | 2024-06-19 | Shionogi & Co., Ltd | 6-membered heterocyclic derivative and pharmaceutical composition comprising same |
| MX2018011136A (es) * | 2016-03-14 | 2019-01-14 | Afferent Pharmaceuticals Inc | Pirimidinas y variantes de estas, y usos de estas. |
| CA3018180C (en) * | 2016-03-25 | 2024-02-20 | Ronald Charles Hawley | Pyrimidines and variants thereof, and uses therefor |
| MX2019004107A (es) | 2016-10-17 | 2019-08-05 | Shionogi & Co | Derivado heterociclico nitrogenado biciclico y composicion farmaceutica que lo contiene. |
| KR20200003328A (ko) | 2018-06-29 | 2020-01-09 | 삼성디스플레이 주식회사 | 디스플레이 장치 |
| AU2019353424B2 (en) | 2018-10-05 | 2022-12-08 | Shionogi & Co., Ltd. | Medicine for treating chronic cough |
| JP6873534B1 (ja) * | 2019-09-19 | 2021-05-19 | 塩野義製薬株式会社 | １，３，５−トリアジン誘導体またはその溶媒和物の結晶およびその製造方法 |
| IL293592A (en) | 2019-12-06 | 2022-08-01 | Vertex Pharma | Transduced tetrahydrofurans as sodium channel modulators |
| TW202203930A (zh) * | 2020-04-03 | 2022-02-01 | 日商塩野義製藥股份有限公司 | 睡眠時呼吸中止症候群治療用醫藥 |
| TW202203929A (zh) | 2020-04-03 | 2022-02-01 | 日商塩野義製藥股份有限公司 | 疼痛治療用醫藥 |
| WO2021230308A1 (ja) | 2020-05-15 | 2021-11-18 | 塩野義製薬株式会社 | 不純物の生成を抑制した医薬組成物 |
| CN115073431B (zh) | 2021-04-14 | 2023-09-05 | 盐野义制药株式会社 | 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物 |
| AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| CN113801097B (zh) * | 2021-09-27 | 2022-11-22 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物、其制备方法及用途 |
| CN113620888B (zh) * | 2021-09-27 | 2023-06-06 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物及其制备方法和应用 |
| CN113773300B (zh) * | 2021-09-27 | 2022-10-11 | 成都施贝康生物医药科技有限公司 | 磺酰胺类化合物、其制备方法及用途 |
| CA3233206A1 (en) | 2021-09-28 | 2023-04-06 | Yuki Tachibana | Pharmaceutical composition containing triazine derivative |
| TW202320793A (zh) | 2021-09-28 | 2023-06-01 | 日商塩野義製藥股份有限公司 | 含有三嗪衍生物之醫藥組合物 |
| EP4289432A1 (en) | 2021-11-24 | 2023-12-13 | Shionogi & Co., Ltd | Preparation for oral administration containing triazine derivative |
| WO2023095860A1 (ja) * | 2021-11-26 | 2023-06-01 | 塩野義製薬株式会社 | ３ｃｌプロテアーゼ阻害剤及びｃｏｖｉｄ－１９治療用薬剤を組み合わせることを特徴とするｃｏｖｉｄ－１９治療用医薬 |
| CN115650959B (zh) * | 2022-05-20 | 2023-10-20 | 南京济群医药科技股份有限公司 | 化合物的制备方法或纯化方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3598815A (en) | 1968-10-25 | 1971-08-10 | Goodrich Co B F | Bis-(hydroxyphenylalkylene) alkyl isocyanurates |
| JPS5132324A (en) | 1974-09-12 | 1976-03-18 | Fuji Photo Film Co Ltd | Netsugenzokankozairyo |
| CH622536A5 (es) | 1976-07-08 | 1981-04-15 | Ciba Geigy Ag | |
| CH623840A5 (es) | 1976-10-18 | 1981-06-30 | Ciba Geigy Ag | |
| US4158724A (en) | 1976-10-18 | 1979-06-19 | Ciba-Geigy Corporation | Tris-tetrazoles as chemical blowing agents |
| GB1599518A (en) | 1977-02-21 | 1981-10-07 | Ici Ltd | 1,3,5-triazine-2,6-diones and pharmaceutical compositions thereof |
| EP0005911B1 (en) | 1978-05-26 | 1982-02-17 | Imperial Chemical Industries Plc | Analgesic 6-acylaminotetrahydro-1,3,5-triazine-2,4-dione derivatives, pharmaceutical compositions thereof, and process for their manufacture |
| JPS57144269A (en) | 1981-03-03 | 1982-09-06 | Taiho Yakuhin Kogyo Kk | Triazine derivative and its preparation |
| EP0110828B1 (de) | 1982-11-26 | 1988-01-20 | Ciba-Geigy Ag | Farbphotographisches Aufzeichnungsmaterial |
| JPS62156110A (ja) | 1985-12-27 | 1987-07-11 | Res Inst For Prod Dev | 測鎖にイソシアヌレ−ト構造を含む吸着能力を有する重合体 |
| JPS62156110U (es) | 1986-03-26 | 1987-10-03 | ||
| RU2057754C1 (ru) | 1989-06-05 | 1996-04-10 | Дайити Фармасьютикал Ко., Лтд. | Гетероциклические соединения или их кислотно-аддитивные соли |
| DE69012653T2 (de) | 1989-06-05 | 1995-02-09 | Daiichi Seiyaku Co | Heterocyclische Triazin- oder Triazolo-Verbindungen mit Serotonin 2-Rezeptor-Antagonisten-Wirkung. |
| DE4141721A1 (de) | 1991-12-18 | 1993-06-24 | Bayer Ag | Substituierte heterocyclyltriazindione |
| JP3542482B2 (ja) | 1997-12-25 | 2004-07-14 | 日研化学株式会社 | ３−アニリノ−２−シクロアルケノン誘導体 |
| AU3343899A (en) | 1998-04-15 | 1999-11-01 | Toshiki Fukuchi | 2-anilinopyrimidinone derivatives, intermediates in the production thereof, process for producing the same and pesticides containing the same as the active ingredient |
| JP2995293B1 (ja) | 1998-08-25 | 1999-12-27 | 工業技術院長 | １，６‐ジ置換‐１，３，５‐トリアジン‐２，４（１ｈ，３ｈ）‐ジオン化合物の製造方法 |
| US6177437B1 (en) | 1998-09-04 | 2001-01-23 | University Of Massachusetts Medical Center | Inhibitors of Herpes Simplex virus uracil-DNA glycosylase |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| EP1159271B1 (en) | 1999-03-04 | 2004-08-25 | Korea Research Institute of Chemical Technology | Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof |
| JP4674676B2 (ja) | 1999-11-08 | 2011-04-20 | 公益財団法人相模中央化学研究所 | ２−置換アミノピリミジノン誘導体、それらの製造方法並びにそれらを有効成分とする殺虫、殺ダニ剤 |
| AU2001227084A1 (en) | 2000-01-25 | 2001-08-07 | Japan Tobacco Inc. | N-arylhydrazide compounds and use thereof as drugs |
| US20020049320A1 (en) | 2000-04-27 | 2002-04-25 | American Cyanamid Company | 6-amino-2,4-dioxo-3,4-dihydro-1,3,5-triazine derivatives and methods for the solid phase synthesis thereof |
| JP2005508288A (ja) | 2001-05-18 | 2005-03-31 | アボット・ラボラトリーズ | Ｐ２ｘ３およびｐ２ｘ２／３含有受容体を阻害するトリ置換−ｎ−［（１ｓ）−１，２，３，４−テトラヒドロ−１−ナフタレニル］ベンズアミド類 |
| AU2003289330A1 (en) | 2002-12-13 | 2004-07-09 | Kyowa Hakko Kogyo Co., Ltd. | Preventives and/or remedies for central diseases |
| WO2005009980A1 (en) | 2003-07-22 | 2005-02-03 | Neurogen Corporation | Substituted pyridin-2-ylamine analogues |
| KR100822530B1 (ko) | 2004-03-05 | 2008-04-16 | 에프. 호프만-라 로슈 아게 | Ｐ2ｘ3 및 ｐ2ｘ2/3 길항물질로서의 다이아미노피리미딘 |
| US20060029548A1 (en) | 2004-07-22 | 2006-02-09 | Amir Pelleg | Methods of diagnosing, monitoring and treating pulmonary diseases |
| JP5208516B2 (ja) | 2004-12-30 | 2013-06-12 | エグゼリクシス， インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
| JP2008537548A (ja) | 2005-03-24 | 2008-09-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | プロキネチシン１受容体 |
| CA2602510A1 (en) | 2005-03-24 | 2006-10-05 | Janssen Pharmaceutica N.V. | Pyrimidindione derivatives as prokineticin 2 receptor antagonists |
| AU2006229793A1 (en) | 2005-03-24 | 2006-10-05 | Janssen Pharmaceutica, N.V. | Prokineticin 1 receptor antagonists |
| WO2006119502A2 (en) | 2005-05-03 | 2006-11-09 | Southwest Research Institute | Lubricant oils and greases containing nanoparticle additives |
| CA2606760C (en) | 2005-05-04 | 2014-12-23 | Renovis, Inc. | Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions |
| EP1917262B1 (en) | 2005-08-15 | 2011-12-14 | F. Hoffmann-La Roche AG | Piperidine and piperazine derivatives as p2x3 antagonists |
| EP1924264B9 (en) | 2005-09-01 | 2014-02-19 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| ES2612890T3 (es) | 2005-09-01 | 2017-05-19 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores de P2X3 y P2X2/3 |
| EP1924566B1 (en) | 2005-09-01 | 2016-01-13 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| CA2619898C (en) | 2005-09-01 | 2014-03-18 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| EP2385042B1 (en) | 2005-12-29 | 2015-11-25 | Janssen Pharmaceutica N.V. | Prokineticin 1 receptor antagonists |
| WO2007079214A2 (en) | 2005-12-29 | 2007-07-12 | Janssen Pharmaceutica N.V. | Prokineticin 2 receptor antagonists |
| AU2007269540B2 (en) | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
| US8106064B2 (en) | 2006-07-24 | 2012-01-31 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-dione HIV reverse transcriptase inhibitors |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| AR065996A1 (es) | 2007-04-13 | 2009-07-15 | Schering Corp | Derivados de pirimidindiona,composiciones farmaceuticas que los conitenen y usos en el tratamiento y/o prevencion de la obesidad, diabetes, dislipidemia entre otras patologias. |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| JP2009007258A (ja) | 2007-06-26 | 2009-01-15 | Kowa Pharmaceutical Co Ltd | Ｐａｉ−１産生抑制作用を有する３−アニリノ−２−シクロアルケノン誘導体 |
| US8324380B2 (en) | 2007-10-30 | 2012-12-04 | Janssen Pharmaceutica Nv | Amino-heteroaryl-containing prokineticin 1 receptor antagonists |
| CN101910169A (zh) | 2008-02-13 | 2010-12-08 | 卫材R&D管理有限公司 | 双环胺衍生物 |
| CA2737038A1 (en) | 2008-09-18 | 2010-03-25 | Evotec Ag | Amide compounds, compositions and uses thereof |
| JP5592388B2 (ja) | 2008-10-31 | 2014-09-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 疼痛治療用のｐ２ｘ３受容体アンタゴニスト技術分野 |
| CN102395571B (zh) * | 2009-02-13 | 2015-12-16 | 盐野义制药株式会社 | 三嗪衍生物及含有该三嗪衍生物的药物组合物 |
| EP2445868B1 (en) | 2009-06-22 | 2013-12-18 | F.Hoffmann-La Roche Ag | Biphenyl amides useful as p2x3 and/or p2x2/3 receptors modulators |
| WO2011017347A2 (en) | 2009-08-05 | 2011-02-10 | E. I. Du Pont De Nemours And Company | Mesoionic pesticides |
| EP2601519B1 (en) | 2010-07-30 | 2017-12-06 | Expression Pathology, Inc. | C-src selected reaction monitoring assay |
| RU2565073C2 (ru) | 2010-08-10 | 2015-10-20 | Сионоги Энд Ко., Лтд. | Триазиновое производное и включающая его фармацевтическая композиция, обладающая анальгетической активностью |
| WO2012020742A1 (ja) | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
| WO2012135800A1 (en) | 2011-04-01 | 2012-10-04 | University Of Utah Research Foundation | Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase |
| TW201331188A (zh) * | 2011-12-15 | 2013-08-01 | Shionogi & Co | 經取代之三□衍生物及含有其之醫藥組成物 |
| JP6124351B2 (ja) | 2012-02-09 | 2017-05-10 | 塩野義製薬株式会社 | 複素環および炭素環誘導体 |
| TWI637949B (zh) * | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
-
2014
- 2014-06-04 TW TW103119435A patent/TWI637949B/zh active
- 2014-06-13 KR KR1020167000768A patent/KR101813411B1/ko active IP Right Grant
- 2014-06-13 ES ES14810134.8T patent/ES2675528T3/es active Active
- 2014-06-13 DK DK14810134.8T patent/DK3009432T3/en active
- 2014-06-13 CA CA2915325A patent/CA2915325C/en active Active
- 2014-06-13 TR TR2018/09085T patent/TR201809085T4/tr unknown
- 2014-06-13 AR ARP140102276A patent/AR096620A1/es unknown
- 2014-06-13 EP EP14810134.8A patent/EP3009432B1/en active Active
- 2014-06-13 WO PCT/JP2014/065678 patent/WO2014200078A1/ja active Application Filing
- 2014-06-13 PL PL14810134T patent/PL3009432T3/pl unknown
- 2014-06-13 US US14/897,836 patent/US9732060B2/en active Active
- 2014-06-13 SG SG11201510179PA patent/SG11201510179PA/en unknown
- 2014-06-13 AU AU2014279116A patent/AU2014279116B2/en active Active
- 2014-06-13 MX MX2015016877A patent/MX362995B/es unknown
- 2014-06-13 KR KR1020177027171A patent/KR20170116177A/ko not_active Application Discontinuation
- 2014-06-13 BR BR112015031079-6A patent/BR112015031079B1/pt active IP Right Grant
- 2014-06-13 EA EA201690019A patent/EA030198B1/ru not_active IP Right Cessation
- 2014-06-13 JP JP2015522870A patent/JP6132371B2/ja active Active
- 2014-06-13 CN CN201480043967.6A patent/CN105452234B/zh active Active
-
2015
- 2015-12-10 IL IL243042A patent/IL243042A0/en unknown
- 2015-12-14 PH PH12015502775A patent/PH12015502775A1/en unknown
-
2017
- 2017-06-29 US US15/637,967 patent/US10065941B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096620A1 (es) | Derivado de aminotriazina y composición farmacéutica que lo comprende | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| SA515361086B1 (ar) | Fasn مركبات وتركيبات جديدة لتثبيط | |
| CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
| MD3313851T2 (ro) | Noi derivați hidroxiester, procedeu pentru prepararea lor și compoziții farmaceutice care îi conțin | |
| CU20180073A7 (es) | Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| MD3313817T2 (ro) | Derivați biciclici, un procedeu pentru prepararea lor și compozițiile farmaceutice care îi conțin | |
| NZ631738A (en) | (hetero) arylacetamide derivatives as antiretroviral agents | |
| BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
| CR20160291A (es) | Análogos de cortistatina y síntesis y usos de los mismos | |
| BR112015022804A2 (pt) | novos derivados de octahidro-pirrol [3,4-c]-pirrol e seus análogos como inibidores de autotaxina | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| BR112016000489A8 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
| MX2015012111A (es) | Moduladores de ship1 y métodos relacionados con éstos. | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| EA201590205A1 (ru) | N-алкил 2-(дизамещенные)алкиниладенозин-5-уронамиды в качестве а-агонистов | |
| PH12015502851B1 (en) | Curable composition | |
| JOP20200030A1 (ar) | مركب خماسي الحلقة | |
| PH12016500152A1 (en) | Novel triazine derivative | |
| AR103444A1 (es) | Forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos | |
| CO6680697A2 (es) | Compuestos heterociclicos para tratar o prevenir transtornos causado por neurotransmisión reducida de serotonina, norepinefrina o dopamina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |